International Diabetes Center at Park Nicollet, 3800 Park Nicollet Blvd, Minneapolis, MN 55416, United States.
Insulet Corporation, 100 Nagog Park, Acton, MA 01720, United States.
Diabetes Res Clin Pract. 2021 Apr;174:108735. doi: 10.1016/j.diabres.2021.108735. Epub 2021 Mar 9.
To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems.
In this retrospective observational study (N = 3,592) change in HbA1c level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE, <70 mg/dL, n = 2,922) were assessed overall and by prior treatment modality (multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)), age group, and baseline HbA1c category.
Change (mean ± SD) in HbA1c was -1.3 ± 1.7% [-14 ± 19 mmol/mol] overall, -1.4 ± 1.7% [-15 ± 19 mmol/mol] for prior MDI users, and -0.9 ± 1.5% [-10 ± 16 mmol/mol] for prior CSII users (p<0.0001). The percentage of patients with HbA1c ≥9% [≥75 mmol/mol] decreased (49% to 19%), and with HbA1c <7% [<53 mmol/mol] increased (10% to 22%) (p<0.0001). Prior therapy, age, and baseline HbA1c category were factors affecting change in HbA1c (p<0.05). Reductions in TDD (overall, -33 ± 52U, p<0.0001) and HE per week (overall, -0.5 ± 2.0, p<0.0001), were seen regardless of prior treatment, age, or baseline HbA1c.
Omnipod System use was associated with statistically and clinically meaningful reductions in HbA1c, TDD, and HE compared to prior treatments in T2DM.
比较 2 型糖尿病（T2DM）患者使用 Omnipod®或 Omnipod DASH®胰岛素管理系统前后的血糖控制结果。
在这项回顾性观察性研究（N=3592）中，总体以及按既往治疗模式（多次皮下注射（MDI）或连续皮下胰岛素输注（CSII））、年龄组和基线糖化血红蛋白（HbA1c）类别评估了 HbA1c 水平、胰岛素总日剂量（TDD，n=3053）和自我报告的低血糖事件（HE，<70mg/dL，n=2922）的变化。
HbA1c 的变化（平均值±标准差）总体为-1.3±1.7%[-14±19mmol/mol]，既往 MDI 使用者为-1.4±1.7%[-15±19mmol/mol]，既往 CSII 使用者为-0.9±1.5%[-10±16mmol/mol]（p<0.0001）。HbA1c≥9%[≥75mmol/mol]的患者比例从 49%降至 19%，HbA1c<7% [<53mmol/mol]的患者比例从 10%增至 22%（p<0.0001）。既往治疗、年龄和基线 HbA1c 类别是影响 HbA1c 变化的因素（p<0.05）。TDD（总体，-33±52U，p<0.0001）和每周 HE（总体，-0.5±2.0，p<0.0001）的减少与既往治疗、年龄或基线 HbA1c 无关。
与既往治疗相比，使用 Omnipod 系统可使 T2DM 患者的 HbA1c、TDD 和 HE 显著降低。
